Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group

T. Andre; D. Vernerey; S. A. Im; G. Bodoky; R. Buzzoni; S. Reingold; F. Rivera; J. McKendrick; W. Scheithauer; G. Ravit; G. Fountzilas; W. P. Yong; R. Isaacs; P. Österlund; J. T. Liang; G. J. Creemers; M. Rakez; E. Van Cutsem; D. Cunningham; J. Tabernero; A. de Gramont

doi:10.1016/j.annonc.2019.12.006

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group

T. Andre, D. Vernerey, S. A. Im, G. Bodoky, R. Buzzoni, S. Reingold, F. Rivera, J. McKendrick, W. Scheithauer, G. Ravit, G. Fountzilas, W. P. Yong, R. Isaacs, P. Österlund, J. T. Liang, G. J. Creemers, M. Rakez, E. Van Cutsem, D. Cunningham, J. TaberneroA. de Gramont

Research output: Contribution to journal › Article › Scientific › peer-review

Original language	English
Journal	Annals of Oncology
Volume	31
Issue number	2
Pages (from-to)	246-256
Number of pages	11
ISSN	0923-7534
DOIs	https://doi.org/10.1016/j.annonc.2019.12.006
Publication status	Published - Feb 2020
MoE publication type	A1 Journal article-refereed

Fields of Science

adjuvant
bevacizumab
colon cancer
FOLFOX
XELOX
OPEN-LABEL
STAGE-II
OXALIPLATIN
FLUOROURACIL
LEUCOVORIN
IRINOTECAN
TRIAL
CHEMOTHERAPY
CAPECITABINE
CARCINOMA
3122 Cancers

Access to Document

10.1016/j.annonc.2019.12.006

Andre et al. SAVANT_SIII_ manuscript 2020Accepted author manuscript, 153 KBLicence: CC BY-NC-ND

Cite this

Andre, T., Vernerey, D., Im, S. A., Bodoky, G., Buzzoni, R., Reingold, S., Rivera, F., McKendrick, J., Scheithauer, W., Ravit, G., Fountzilas, G., Yong, W. P., Isaacs, R., Österlund, P., Liang, J. T., Creemers, G. J., Rakez, M., Van Cutsem, E., Cunningham, D., ... de Gramont, A. (2020). Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group. Annals of Oncology, 31(2), 246-256. https://doi.org/10.1016/j.annonc.2019.12.006

@article{57eabb6617e24433b2276f95385f49ec,

title = "Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group",

keywords = "adjuvant, bevacizumab, colon cancer, FOLFOX, XELOX, OPEN-LABEL, STAGE-II, OXALIPLATIN, FLUOROURACIL, LEUCOVORIN, IRINOTECAN, TRIAL, CHEMOTHERAPY, CAPECITABINE, CARCINOMA, 3122 Cancers",

author = "T. Andre and D. Vernerey and Im, {S. A.} and G. Bodoky and R. Buzzoni and S. Reingold and F. Rivera and J. McKendrick and W. Scheithauer and G. Ravit and G. Fountzilas and Yong, {W. P.} and R. Isaacs and P. {\"O}sterlund and Liang, {J. T.} and Creemers, {G. J.} and M. Rakez and {Van Cutsem}, E. and D. Cunningham and J. Tabernero and {de Gramont}, A.",

year = "2020",

month = feb,

doi = "10.1016/j.annonc.2019.12.006",

language = "English",

volume = "31",

pages = "246--256",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "2",

}

Andre, T, Vernerey, D, Im, SA, Bodoky, G, Buzzoni, R, Reingold, S, Rivera, F, McKendrick, J, Scheithauer, W, Ravit, G, Fountzilas, G, Yong, WP, Isaacs, R, Österlund, P, Liang, JT, Creemers, GJ, Rakez, M, Van Cutsem, E, Cunningham, D, Tabernero, J & de Gramont, A 2020, 'Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group', Annals of Oncology, vol. 31, no. 2, pp. 246-256. https://doi.org/10.1016/j.annonc.2019.12.006

TY - JOUR

T1 - Bevacizumab as adjuvant treatment of colon cancer

T2 - updated results from the S-AVANT phase III study by the GERCOR Group

AU - Andre, T.

AU - Vernerey, D.

AU - Im, S. A.

AU - Bodoky, G.

AU - Buzzoni, R.

AU - Reingold, S.

AU - Rivera, F.

AU - McKendrick, J.

AU - Scheithauer, W.

AU - Ravit, G.

AU - Fountzilas, G.

AU - Yong, W. P.

AU - Isaacs, R.

AU - Österlund, P.

AU - Liang, J. T.

AU - Creemers, G. J.

AU - Rakez, M.

AU - Van Cutsem, E.

AU - Cunningham, D.

AU - Tabernero, J.

AU - de Gramont, A.

PY - 2020/2

Y1 - 2020/2

KW - adjuvant

KW - bevacizumab

KW - colon cancer

KW - FOLFOX

KW - XELOX

KW - OPEN-LABEL

KW - STAGE-II

KW - OXALIPLATIN

KW - FLUOROURACIL

KW - LEUCOVORIN

KW - IRINOTECAN

KW - TRIAL

KW - CHEMOTHERAPY

KW - CAPECITABINE

KW - CARCINOMA

KW - 3122 Cancers

U2 - 10.1016/j.annonc.2019.12.006

DO - 10.1016/j.annonc.2019.12.006

M3 - Article

SN - 0923-7534

VL - 31

SP - 246

EP - 256

JO - Annals of Oncology

JF - Annals of Oncology

IS - 2

ER -